Immatics (NASDAQ:IMTX) Sees Unusually-High Trading Volume

Immatics (NASDAQ:IMTX) saw strong trading volume on Friday . 277,547 shares changed hands during trading, a decline of 43% from the previous session’s volume of 490,941 shares.The stock last traded at $10.52 and had previously closed at $9.82.

Analyst Ratings Changes

Separately, Mizuho increased their target price on Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th.

Immatics Stock Performance

The stock has a market cap of $950.73 million, a PE ratio of -10.10 and a beta of 0.69. The stock has a fifty day moving average price of $10.76 and a 200 day moving average price of $10.71.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Immatics had a negative return on equity of 29.36% and a negative net margin of 107.80%. The firm had revenue of $17.14 million during the quarter, compared to analyst estimates of $11.78 million. As a group, equities analysts anticipate that Immatics will post -1.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immatics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. bought a new position in shares of Immatics in the 1st quarter worth $18,392,000. Zimmer Partners LP grew its stake in Immatics by 89.0% during the 1st quarter. Zimmer Partners LP now owns 397,000 shares of the company’s stock worth $4,172,000 after buying an additional 187,000 shares during the last quarter. Baker BROS. Advisors LP grew its stake in Immatics by 10.4% during the 1st quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock worth $67,720,000 after buying an additional 604,545 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Immatics by 38.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after buying an additional 891,191 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in Immatics by 75.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 350,000 shares of the company’s stock worth $3,678,000 after buying an additional 150,000 shares during the last quarter. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.